| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 27.82 | 1.4% | 28.2% |
| Total Income | 27.82 | 1.4% | 28.2% |
| Expenditure | 18.82 | 1.5% | 36.1% |
| PBT | -2.24 | 43.6% | 91.9% |
| Net Profit | -2.33 | 41.3% | 92.2% |
| OPM | -11.62% | 3.19pp | 60.67pp |
| NPM | -8.37% | 5.70pp | 68.83pp |
| EPS | -0.16 | 42.9% | 92.1% |
Anika Reports Q3 2025 Revenue of $27.8M, Down 6% YoY
04 May 2026 · 4 May, 8:05 am
Summary
Anika Therapeutics reported a 6% decrease in third-quarter revenue, totaling $27.8 million compared to the same period in 2024. The Commercial Channel experienced a 22% increase, while the OEM Channel saw a 20% decrease. The company reaffirmed its fiscal year 2025 guidance and initiated a $15 million share repurchase program. Cingal reached a milestone of over one million injections globally since 2016.
Key Highlights
- 1
Anika reported third quarter revenue from continuing operations of $27.8 million, a 6% decrease compared to the same period in 2024.
- 2
Commercial Channel revenue increased 22% year over year, driven by Integrity™ Implant System and Hyalofast® growth.
- 3
OEM Channel revenue decreased 20% year over year, impacted by lower U.S. pricing for Monovisc® and Orthovisc®.
- 4
Regenerative Solutions revenue increased 25% in the quarter, driven by Integrity’s outperformance.
- 5
Anika reaffirmed its fiscal year 2025 guidance and long-term outlook.
- 6
The company commenced a $15 million 10b5-1 share repurchase program.
- 7
Cingal® achieved a commercial milestone of more than one million injections worldwide since 2016.
Management Comments
Cheryl Blanchard
"We continue to see strength in our Commercial Channel with Regenerative Solutions revenue increasing 25% in the quarter driven by Integrity’s outperformance, continued strong international Hyalofast growth, and double-digit International OA Pain Management revenue growth. Third quarter pricing for U.S. OA Pain Management products was in line with expectations, and we anticipate the full year to be in line with our prior guidance. In addition, J&J MedTech has exercised its option to continue our license and supply agreement for Monovisc for another 5-year term through December 2031. During the quarter, Cingal reached a significant commercial milestone, surpassing 1 million injections globally since launch. Finally, we continued to take actions to improve our operating expense profile, with Selling, General and Administrative expenses down 12% year over year, and overall operating expenses down 3%, as we continue to work to improve our profitability and free cash flow."
Informational and educational content only. Not investment advice.